|
|
 |
|
|
|
|
52. M. J. Boddington. An absolute metabolic scope for activity. J. Theor. Biol. 75: 443449, 1978. |
|
|
|
|
|
|
|
|
53. H. Boxenbaum. Time concepts in physics, biology and pharmacokinetics. J. Pharm. Sci. 75: 10531062, 1986. |
|
|
|
|
|
|
|
|
54. A. S. Hussain, R. D. Johnson, N. N. Vachharajani, and W. A. Ritshel. Feasibility of developing a neural network for the prediction of human pharmacokinetic parameters from animal data. Pharmaceutical Research 10: 466469, 1993. |
|
|
|
|
|
|
|
|
55. ICH3 Harmonisation Meeting, Yokahama, Japan, November 1995. |
|
|
|
|
|
|
|
|
56. D. B. Campbell. Are we doing too many animal biodisposition investigations before Phase I studies in man? A re-evaluation of the timing and extent of ADME studies. European Journ. of Drug Metabolism and Pharmacokinetics 19: 283293, 1994. |
|
|
|
|
|
|
|
|
57. A. Warrander. Harmonisation of preclinical metabolism and pharmacokinetic: Interim results of questionnaire. ISSX Newsletter 12(1): 1213, 1993. |
|
|
|
|
|
|
|
|
58. A. Warrander. Around the world with 80+ companiesA review of toxicokinetic practices. Drug. Inf. J. 28: 281283, 1994. |
|
|
|
|
|
|
|
|
59. ICH2. Draft Consensus Text. Toxicokinetics: Guidance for Repeated Dose Tissue Distribution Studies. Released for consultation 27 October 1993 at Step 2 of the ICH Process, 1993a. |
|
|
|
|
|
|
|
|
60. N. Motoji, E. Hatama, and A. Shigematsu. Radioluminography for quantitative autoradiography of 14C. E. J. Drug. Metab. Pharmacokin. 20: 89105, 1995. |
|
|
|
|
|
|
|
|
61. D. B. Campbell. The use of kinetic-dynamic interactions in the evaluation of drugs. Phychopharmacology 100: 433450, 1990. |
|
|
|
|
|
|
|
|
62. D. B. Campbell. The use of toxicokinetics for the safety assessment of drugs acting in the brain. Molec. Neurobiol. 11: 193216, 1995b. |
|
|
|
|
|
|
|
|
63. K. Kobayashi, D. I. Jodrell, and M. J. Ratain. Pharmacodynamic-Pharmacokinetic Relationships and Therapeutic Drug Monitoring Cancer Surveys 17: Pharmacokinetics and Cancer Chemotherapy Imperial Cancer Research Fund, p. 5178, 1993. |
|
|
|
|
|
|
|
|
64. J. M. Collins, C. K. Grieshaber, and B. A. Chabner. Pharmacologically guided Phase 1 clinical trials based upon preclinical drug development. J. Nat. Cancer Instit. 82: 13211326, 1990. |
|
|
|
|
|
|
|
|
65. N. H. Holford and L. B. Shiener. Pharmacokinetic and pharmacodynamic modelling in vivo. CRC Critical Reviews in Bioengineering 5: 273322, 1981. |
|
|
|
|
|
|
|
|
66. L. B. Sheiner, D. R. Stanski, S. Vozeh, R. D. Miller, and J. Ham. Simultaneous modelling of pharmaco-kinetics and pharmacodynamics: application to d-tubocurarine. Clin. Pharm. Ther. 25: 358371, 1979. |
|
|
|
|
|
|
|
|
67. L. B. Sheiner. Modeling pharmacodynamics: parametric and nonparametric approaches. In Variability in Drug Therapy: Description, Estimation and Control. M. Rowland, L. B. Scheiner, and J. L. Steiner, Eds. Raven Press, New York, 1985, p. 139152. |
|
|
|
|
|
|
|
|
68. SIPHAR. Simed, 9211 rue G. Enesio, 94008 Creteil, France. |
|
|
|
|
|
|
|
|
69. B. M. Barnhill. Micro NONLIN for MS DOS computers: Non-linear regression analysis. Pittsburgh PA, Elite Software, 1984. |
|
|
|
|
|
|
|
|
70. D. Z. D'Arenio and A. Schumitzky. A program package for simulation and parameter estimation in pharmacokinetics system. Computer Programs in Biomedicine 9: 115134, 1979. |
|
|
|
|
|